Merck acquires OncoEthix for up to $375 million

Merck acquires privately-held, Swiss-based biotechnology company OncoEthix for up to $375 million, its latest push into the oncology market.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.